Is the Ramsay Health Care share price in the buy zone?

Is it time for investors to buy Ramsay Health Care Limited (ASX: RHC) with the share price just below its 52-week high?

The Ramsay Health Care Limited (ASX: RHC) share price has been a strong performer over the last several weeks. Shares in the private hospital operator have risen 11% to $72.30 since the Federal election on 18 May, despite no market sensitive announcement being released since March.

Prior to the election, the Labor Party had announced a policy of putting a 2% cap on premium increases by private health insurers, which was priced into Ramsay's share price.

There were concerns that private health insurers would place additional pressure on private hospital operators such as Ramsay to lower prices in order to compensate for the capped premium increases. This would have materially impacted Ramsay's margins and future profitability. 

The election result has seen a reversal of fortunes in the sector, as business is expected to continue as usual moving forward. Similarly, investors have also become bullish on private health insurers such as Medibank Private Ltd (ASX: MPL) and NIB Holdings Limited (ASX: NHF), which have seen their share prices rise 20% and 32%, respectively, since the Federal election. 

a woman

Is this a return to double-digit earnings growth? 

Ramsay has guided for a soft FY19 by its own standards with management reaffirming core earnings per share growth of up to 2% including the Capio acquisition in February. The purchase of Capio is expected to be dilutive to earnings in FY19 and accretive within 2 or 3 years as Ramsay focuses on achieving synergies from the acquisition. 

The market is currently pricing in an acceleration in earnings growth for FY20, with the current earnings per share consensus for FY20 at $3.16. This would represent earnings growth of around 10% over the current FY19 consensus forecast of $2.87, and a return to the double-digit earnings growth that the company has delivered on a relatively consistent basis over the last decade. 

Foolish takeaway

For long-term shareholders, demand from the ageing population is expected to drive growth in the sector and Ramsay continues to maintain a market-leading position in Australia, which remains the largest contributor to group profitability. 

However, at 23 times forward earnings, shares in Ramsay are not cheap and a lot of bullishness is baked in at current prices. As a result, I would view Ramsay as a hold and would wait until the company updates the market on its expectations for FY20 before reassessing. 

Motley Fool contributor Tim Katavic owns shares of Ramsay Health Care Limited. The Motley Fool Australia has recommended NIB Holdings Limited and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »